China Resources Double-Crane Pharmaceutical Co.,Ltd. Logo

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062.SS

(3.2)
Stock Price

20,74 CNY

10.69% ROA

12.08% ROE

14.21x PER

Market Cap.

18.188.481.127,00 CNY

2.49% DER

1.65% Yield

12.84% NPM

China Resources Double-Crane Pharmaceutical Co.,Ltd. Stock Analysis

China Resources Double-Crane Pharmaceutical Co.,Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 DER

The stock has a minimal amount of debt (2%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

5 ROE

ROE in an average range (12.08%) suggests satisfactory profitability and decent utilization of shareholders' equity.

6 PBV

The stock's PBV ratio (1.68x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

7 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

8 Net Profit Growth

This company's net profit has been consistently on the rise over the past three years, indicating a strong financial performance and making it an appealing investment opportunity.

9 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (108) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

China Resources Double-Crane Pharmaceutical Co.,Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Revenue
Year Revenue Growth
1994 156.723.633
1995 168.110.604 6.77%
1996 208.444.950 19.35%
1997 236.308.870 11.79%
1998 350.665.652 32.61%
1999 723.168.281 51.51%
2000 1.168.339.074 38.1%
2001 2.382.656.799 50.96%
2002 3.686.321.221 35.36%
2003 4.249.211.383 13.25%
2004 4.195.715.448 -1.28%
2005 4.597.428.999 8.74%
2006 4.049.090.024 -13.54%
2007 4.556.616.381 11.14%
2008 4.951.524.368 7.98%
2009 5.037.946.418 1.72%
2010 5.366.795.812 6.13%
2011 6.383.375.275 15.93%
2012 6.989.323.408 8.67%
2013 6.834.574.326 -2.26%
2014 4.280.960.954 -59.65%
2015 5.138.395.402 16.69%
2016 5.494.803.869 6.49%
2017 6.421.846.769 14.44%
2018 8.225.083.313 21.92%
2019 9.380.989.928 12.32%
2020 8.503.938.230 -10.31%
2021 9.111.516.931 6.67%
2022 9.446.925.267 3.55%
2023 9.246.989.024 -2.16%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1994 0
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 50.189.155 100%
2011 54.852.420 8.5%
2012 45.760.738 -19.87%
2013 58.669.830 22%
2014 88.642.908 33.81%
2015 143.801.922 38.36%
2016 120.554.948 -19.28%
2017 152.196.368 20.79%
2018 144.740.640 -5.15%
2019 202.006.719 28.35%
2020 291.018.163 30.59%
2021 409.592.541 28.95%
2022 474.719.364 13.72%
2023 548.338.254 13.43%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

China Resources Double-Crane Pharmaceutical Co.,Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1994 4.762.954
1995 6.444.944 26.1%
1996 11.269.244 42.81%
1997 17.356.915 35.07%
1998 36.010.216 51.8%
1999 93.267.892 61.39%
2000 142.621.913 34.6%
2001 262.547.915 45.68%
2002 366.668.363 28.4%
2003 395.238.756 7.23%
2004 435.430.782 9.23%
2005 349.332.144 -24.65%
2006 361.684.620 3.42%
2007 224.676.626 -60.98%
2008 290.883.522 22.76%
2009 292.321.777 0.49%
2010 90.664.311 -222.42%
2011 112.480.437 19.4%
2012 124.010.986 9.3%
2013 157.605.748 21.32%
2014 97.636.708 -61.42%
2015 119.328.537 18.18%
2016 118.423.135 -0.76%
2017 114.803.157 -3.15%
2018 125.928.768 8.83%
2019 123.654.438 -1.84%
2020 118.405.552 -4.43%
2021 148.787.473 20.42%
2022 131.064.503 -13.52%
2023 2.335.128.258 94.39%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

China Resources Double-Crane Pharmaceutical Co.,Ltd. EBITDA
Year EBITDA Growth
1994 -14.103.571
1995 47.998.244 129.38%
1996 53.622.657 10.49%
1997 47.831.982 -12.11%
1998 81.478.483 41.29%
1999 165.170.137 50.67%
2000 240.374.245 31.29%
2001 300.752.585 20.08%
2002 332.482.750 9.54%
2003 255.977.712 -29.89%
2004 198.391.655 -29.03%
2005 408.308.136 51.41%
2006 379.788.482 -7.51%
2007 614.611.818 38.21%
2008 615.313.961 0.11%
2009 723.767.003 14.98%
2010 818.564.054 11.58%
2011 922.777.538 11.29%
2012 1.036.832.657 11%
2013 1.385.285.818 25.15%
2014 912.900.032 -51.75%
2015 1.116.254.997 18.22%
2016 1.261.426.487 11.51%
2017 1.430.755.821 11.83%
2018 1.552.319.988 7.83%
2019 1.689.753.674 8.13%
2020 1.673.771.581 -0.95%
2021 1.627.938.318 -2.82%
2022 1.988.439.579 18.13%
2023 1.491.986.789 -33.27%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Gross Profit
Year Gross Profit Growth
1994 49.721.438
1995 64.742.913 23.2%
1996 77.337.133 16.28%
1997 75.403.741 -2.56%
1998 123.425.561 38.91%
1999 275.629.220 55.22%
2000 534.352.664 48.42%
2001 882.230.402 39.43%
2002 1.141.500.381 22.71%
2003 1.152.399.836 0.95%
2004 1.109.804.081 -3.84%
2005 1.232.270.907 9.94%
2006 1.146.314.208 -7.5%
2007 1.370.362.109 16.35%
2008 1.533.799.387 10.66%
2009 1.710.350.162 10.32%
2010 1.941.859.991 11.92%
2011 2.061.907.514 5.82%
2012 2.327.873.279 11.43%
2013 2.364.616.899 1.55%
2014 2.074.978.774 -13.96%
2015 2.665.272.598 22.15%
2016 2.918.308.606 8.67%
2017 3.688.104.503 20.87%
2018 5.210.657.202 29.22%
2019 5.950.346.789 12.43%
2020 5.358.746.646 -11.04%
2021 5.081.544.181 -5.46%
2022 5.215.110.318 2.56%
2023 4.944.475.897 -5.47%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Net Profit
Year Net Profit Growth
1994 31.461.720
1995 43.988.137 28.48%
1996 50.662.675 13.17%
1997 47.549.019 -6.55%
1998 60.877.848 21.89%
1999 75.885.352 19.78%
2000 128.914.739 41.14%
2001 157.710.419 18.26%
2002 168.442.069 6.37%
2003 64.630.630 -160.62%
2004 4.705.283 -1273.58%
2005 186.639.285 97.48%
2006 164.893.391 -13.19%
2007 437.580.763 62.32%
2008 380.572.486 -14.98%
2009 451.456.597 15.7%
2010 520.094.651 13.2%
2011 528.998.583 1.68%
2012 614.408.188 13.9%
2013 870.690.216 29.43%
2014 541.907.854 -60.67%
2015 661.063.517 18.02%
2016 714.210.861 7.44%
2017 842.612.497 15.24%
2018 968.593.388 13.01%
2019 1.055.123.709 8.2%
2020 1.005.161.634 -4.97%
2021 935.685.483 -7.43%
2022 1.163.649.615 19.59%
2023 1.203.882.522 3.34%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1994 0
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1 0%
2008 0 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 100%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 100%
2020 1 0%
2021 1 0%
2022 1 100%
2023 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Free Cashflow
Year Free Cashflow Growth
1998 -144.070.546
1999 61.673.987 333.6%
2000 85.975.869 28.27%
2001 -34.573.128 348.68%
2002 -111.353.936 68.95%
2003 -227.046.017 50.96%
2004 256.878.651 188.39%
2005 12.640.511 -1932.19%
2006 132.050.030 90.43%
2007 99.285.586 -33%
2008 22.508.802 -341.1%
2009 56.853.791 60.41%
2010 139.496.247 59.24%
2011 172.743.583 19.25%
2012 174.158.231 0.81%
2013 328.563.431 46.99%
2014 575.996.095 42.96%
2015 532.861.572 -8.09%
2016 661.204.399 19.41%
2017 1.032.272.434 35.95%
2018 1.240.349.781 16.78%
2019 1.198.142.397 -3.52%
2020 1.012.070.296 -18.39%
2021 849.249.628 -19.17%
2022 816.135.880 -4.06%
2023 237.218.894 -244.04%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Operating Cashflow
Year Operating Cashflow Growth
1998 -13.782.428
1999 131.535.430 110.48%
2000 172.805.379 23.88%
2001 141.011.420 -22.55%
2002 140.634.509 -0.27%
2003 148.936.978 5.57%
2004 453.715.358 67.17%
2005 139.775.070 -224.6%
2006 303.708.790 53.98%
2007 235.458.162 -28.99%
2008 331.710.145 29.02%
2009 342.013.845 3.01%
2010 509.674.695 32.9%
2011 511.526.105 0.36%
2012 396.048.303 -29.16%
2013 546.240.145 27.5%
2014 718.376.437 23.96%
2015 701.346.760 -2.43%
2016 771.247.823 9.06%
2017 1.187.087.991 35.03%
2018 1.469.039.631 19.19%
2019 1.439.788.471 -2.03%
2020 1.360.158.210 -5.85%
2021 1.340.920.964 -1.43%
2022 1.341.669.648 0.06%
2023 378.293.251 -254.66%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Capital Expenditure
Year Capital Expenditure Growth
1998 130.288.117
1999 69.861.443 -86.5%
2000 86.829.510 19.54%
2001 175.584.548 50.55%
2002 251.988.445 30.32%
2003 375.982.995 32.98%
2004 196.836.707 -91.01%
2005 127.134.559 -54.83%
2006 171.658.760 25.94%
2007 136.172.576 -26.06%
2008 309.201.343 55.96%
2009 285.160.055 -8.43%
2010 370.178.448 22.97%
2011 338.782.522 -9.27%
2012 221.890.072 -52.68%
2013 217.676.714 -1.94%
2014 142.380.343 -52.88%
2015 168.485.187 15.49%
2016 110.043.424 -53.11%
2017 154.815.557 28.92%
2018 228.689.850 32.3%
2019 241.646.073 5.36%
2020 348.087.914 30.58%
2021 491.671.336 29.2%
2022 525.533.769 6.44%
2023 141.074.358 -272.52%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Equity
Year Equity Growth
1994 94.909.190
1995 103.122.702 7.96%
1996 105.814.127 2.54%
1997 472.914.989 77.63%
1998 533.997.391 11.44%
1999 692.213.789 22.86%
2000 790.559.028 12.44%
2001 1.282.758.453 38.37%
2002 1.404.196.234 8.65%
2003 1.491.802.742 5.87%
2004 1.538.397.122 3.03%
2005 1.727.869.656 10.97%
2006 1.815.543.541 4.83%
2007 2.197.472.999 17.38%
2008 3.079.544.848 28.64%
2009 3.470.516.737 11.27%
2010 3.863.151.455 10.16%
2011 4.257.680.382 9.27%
2012 4.653.606.328 8.51%
2013 5.332.737.412 12.74%
2014 5.679.125.252 6.1%
2015 6.106.660.305 7%
2016 6.686.214.420 8.67%
2017 7.456.791.302 10.33%
2018 7.908.595.969 5.71%
2019 8.676.558.852 8.85%
2020 9.376.986.115 7.47%
2021 10.476.551.365 10.5%
2022 10.729.645.709 2.36%
2023 11.543.869.967 7.05%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Assets
Year Assets Growth
1994 131.334.189
1995 132.290.222 0.72%
1996 154.303.967 14.27%
1997 574.691.007 73.15%
1998 741.017.676 22.45%
1999 1.184.830.570 37.46%
2000 1.484.156.306 20.17%
2001 2.746.287.258 45.96%
2002 3.616.464.655 24.06%
2003 4.257.868.194 15.06%
2004 4.025.259.970 -5.78%
2005 3.813.293.725 -5.56%
2006 3.259.319.827 -17%
2007 3.673.463.375 11.27%
2008 4.269.021.556 13.95%
2009 4.716.974.624 9.5%
2010 5.205.508.965 9.38%
2011 6.076.968.476 14.34%
2012 6.507.775.644 6.62%
2013 6.480.915.882 -0.41%
2014 6.619.296.297 2.09%
2015 7.763.107.207 14.73%
2016 8.241.549.951 5.81%
2017 9.437.896.363 12.68%
2018 10.306.170.916 8.42%
2019 11.276.864.762 8.61%
2020 12.416.486.665 9.18%
2021 13.676.050.323 9.21%
2022 14.482.536.657 5.57%
2023 15.047.462.697 3.75%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Liabilities
Year Liabilities Growth
1994 36.425.000
1995 29.167.520 -24.88%
1996 48.489.841 39.85%
1997 101.776.018 52.36%
1998 199.567.230 49%
1999 473.601.826 57.86%
2000 628.885.609 24.69%
2001 1.256.281.189 49.94%
2002 2.011.551.746 37.55%
2003 2.541.237.564 20.84%
2004 2.297.934.228 -10.59%
2005 1.874.026.289 -22.62%
2006 1.264.114.293 -48.25%
2007 1.308.775.652 3.41%
2008 1.118.558.272 -17.01%
2009 1.182.187.563 5.38%
2010 1.279.581.246 7.61%
2011 1.733.666.651 26.19%
2012 1.801.041.395 3.74%
2013 1.144.690.142 -57.34%
2014 934.925.735 -22.44%
2015 1.329.198.569 29.66%
2016 1.203.050.902 -10.49%
2017 1.589.332.885 24.3%
2018 2.397.574.947 33.71%
2019 2.600.305.910 7.8%
2020 3.039.500.550 14.45%
2021 3.199.498.958 5%
2022 3.752.890.948 14.75%
2023 3.503.592.730 -7.12%

China Resources Double-Crane Pharmaceutical Co.,Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
9.62
Net Income per Share
1.24
Price to Earning Ratio
14.21x
Price To Sales Ratio
1.85x
POCF Ratio
12.19
PFCF Ratio
18.87
Price to Book Ratio
1.65
EV to Sales
1.58
EV Over EBITDA
10.33
EV to Operating CashFlow
10.53
EV to FreeCashFlow
16.07
Earnings Yield
0.07
FreeCashFlow Yield
0.05
Market Cap
18,19 Bil.
Enterprise Value
15,50 Bil.
Graham Number
17.18
Graham NetNet
2.52

Income Statement Metrics

Net Income per Share
1.24
Income Quality
2.64
ROE
0.12
Return On Assets
0.08
Return On Capital Employed
0.12
Net Income per EBT
0.86
EBT Per Ebit
1.01
Ebit per Revenue
0.15
Effective Tax Rate
0.13

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.05
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.55
Operating Profit Margin
0.15
Pretax Profit Margin
0.15
Net Profit Margin
0.13

Dividends

Dividend Yield
0.02
Dividend Yield %
1.65
Payout Ratio
0.48
Dividend Per Share
0.29

Operating Metrics

Operating Cashflow per Share
1.44
Free CashFlow per Share
0.94
Capex to Operating CashFlow
-0.34
Capex to Revenue
-0.05
Capex to Depreciation
0
Return on Invested Capital
0.11
Return on Tangible Assets
0.11
Days Sales Outstanding
92.76
Days Payables Outstanding
58.42
Days of Inventory on Hand
139.24
Receivables Turnover
3.93
Payables Turnover
6.25
Inventory Turnover
2.62
Capex per Share
-0.5

Balance Sheet

Cash per Share
3,29
Book Value per Share
10,61
Tangible Book Value per Share
8.13
Shareholders Equity per Share
10.61
Interest Debt per Share
0.28
Debt to Equity
0.02
Debt to Assets
0.02
Net Debt to EBITDA
-1.79
Current Ratio
2.54
Tangible Asset Value
8,31 Bil.
Net Current Asset Value
4,06 Bil.
Invested Capital
0.02
Working Capital
4,59 Bil.
Intangibles to Total Assets
0.22
Average Receivables
2,53 Bil.
Average Payables
0,76 Bil.
Average Inventory
1778233842.95
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

China Resources Double-Crane Pharmaceutical Co.,Ltd. Dividends
Year Dividends Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 1 0%
2023 0 0%

China Resources Double-Crane Pharmaceutical Co.,Ltd. Profile

About China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People's Republic of China. The company offers soft bag, plastic and glass bottle, inner sealed polypropylene, and polypropylene blend bag infusion products; levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, sodium chloride injection products, etc.; and peritoneal dialysate, hemodialysis dialysate, etc. It also provides compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, edaravone, and other products to treat cardiovascular and cerebrovascular diseases. In addition, the company offers products for endocrinology; and pediatric compound amino acid injection, and other drugs to treat pediatrics. Further, it provides nutritional drugs, including vitamin E and C; and anti-infective drugs. The company is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. is a subsidiary of Beijing Pharmaceutical Group Co., Ltd.

CEO
Mr. Wenchao Lu
Employee
11.821
Address
No. 1, Lize East 2nd Road
Beijing, 100102

China Resources Double-Crane Pharmaceutical Co.,Ltd. Executives & BODs

China Resources Double-Crane Pharmaceutical Co.,Ltd. Executives & BODs
# Name Age
1 Ms. Ziqin Liu
Vice President
70
2 Ms. Donghan Yao
Vice President
70
3 Mr. Wenchao Lu
President & Director
70
4 Mr. Chao Man
Vice President
70

China Resources Double-Crane Pharmaceutical Co.,Ltd. Competitors